Group 1 - The core point of the article is that Opcon Vision (300595) reported a total of 63,118 shareholders as of January 20, 2026 [1]

Core Viewpoint - The company, Opcon Vision, has no plans to change its name, emphasizing the brand's long-standing presence and trust within the industry and among consumers [1] Brand Value - The name "Opcon Vision" has been associated with the company's development for many years, contributing to a strong brand reputation and market recognition [1] Trust and Stability - The company highlights the importance of brand heritage, the stability of its existing trademark system, and the compatibility of its full industry chain business layout in its decision to maintain the current name [1]

Group 1 - The company, Opcon Vision (300595), stated on its interactive platform that it will disclose any external investment matters according to regulations [1]

Group 1 - The company OPPLE Vision (300595.SZ) is currently in the small batch supply phase for its product "Duozhi" and has not yet reached full-scale production [1] - The company's self-owned brand is in preparation, indicating future product launches [1] - Eye health products have been sold to Southeast Asia through cross-border e-commerce and are currently in the promotion stage [1] Group 2 - The audio glasses from the company's associate, Leo Huiding, have just been launched for sale [1] - The company will disclose any investment or acquisition matters according to regulations [1]

Policy Developments - The State Administration for Market Regulation has approved the national standard for "Classification and Determination of Traditional Chinese Medicine Constitution," which will be implemented from April 1. This standard categorizes nine basic types of TCM constitution and aims to enhance health literacy and optimize health service models [2]. Medical Device Approvals - Opcon Vision's application for the registration of "soft hydrophilic contact lenses" has been accepted by the National Medical Products Administration, currently in the acceptance phase [4]. - Livzon Pharmaceutical announced that its clinical trial application for injectable brexpiprazole microspheres for treating schizophrenia has been accepted by the National Medical Products Administration [5]. Capital Markets - AstraZeneca will acquire the remaining 50% equity of Westman Biotech's GPC3 armored CAR-T therapy in China, with a potential payment of up to $630 million, including upfront and milestone payments [7]. - Aote Biological's controlling shareholder has proposed a share buyback plan using funds from its IPO, with a total amount between RMB 100 million and RMB 200 million [8]. Industry Developments - Alibaba Health has launched its self-developed AI medical model "Hydrogen Ion," which is now in practical application, targeting clinical and research fields. This move complements Alibaba's existing health service strategies [10][11]. - Jiangzhong Pharmaceutical has changed its name to "China Resources Jiangzhong Pharmaceutical Co., Ltd." and will also change its stock abbreviation to "China Resources Jiangzhong," while keeping the stock code unchanged [12]. Shareholder Actions - Liaoning He Eye Hospital Group has received a notice from a major shareholder planning to reduce its stake by up to 3,106,074 shares, representing 1.97% of the total share capital, between February 7 and May 6, 2026 [14].

证券代码：300595 证券简称：欧普康视 公告编号：2026-003 1、受理号：CQZ2600102 2、产品名称：软性亲水接触镜 3、注册分类：境内Ⅲ类 欧普康视科技股份有限公司 关于申报医疗器械注册证获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局出具的《受理通知书》，公司申请医疗器械产品"软性亲水接触镜"注册 申请已获国家药品监督管理局受理。具体情况如下： 一、申请注册产品基本情况 4、临床用途：日戴，矫正屈光不正 5、申请人：欧普康视科技股份有限公司 6、结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、产品的审批流程 1、目前所处注册审批阶段：注册申请受理。 2、后续所需审批流程：技术审评。 三、同类医疗器械的市场状况 1、同类医疗器械在国内外的研究现状 软性亲水接触镜的临床研究在国外已有多年，此产品为含水量 60%的日抛透 明彩片，设计为多焦设计，配戴美观舒适，同时具有良好的视力矫正效果。 2、同类医疗器械在国内外的生产 ...

Shareholder Reductions - RS Technologies and Cangyuan Investment plan to reduce their holdings by no more than 3% in Youyan Silicon [1] - Yuexiu Capital intends to sell no more than 1% of the total share capital of CITIC Securities [1] - Multiple shareholders of Ruimaite plan to collectively reduce their holdings by no more than 4.98% [1] - The controlling shareholder of Brother Technology plans to reduce its holdings by no more than 2% [1] - Jinggangshan Chengxing intends to reduce its holdings in Guanggang Gas by no more than 0.9997% [1] - The controlling shareholder of Lianchuang Optoelectronics, Electronic Group, plans to reduce its holdings by no more than 2% [1] - Shenzhen Jun Tian, a shareholder of Chengdu Xian Dao, plans to reduce its holdings by no more than 2.51% [1] - Shareholder Fan Jun of Xidi Micro plans to reduce no more than 251,230 shares [1] - Shareholder Cheng Gao Century of Decai Co., Ltd. plans to reduce 4.1973 million shares [1] - Hangzhou Xintou and its concerted action party Hangzhou Haoyue have cumulatively reduced 1.29% of shares in Meinian Health [1] - Guotou Chuangye Fund has cumulatively reduced 1.06% of shares in Fuchuang Precision [1] - New Momentum Fund has cumulatively reduced 0.9926% of shares in Shannon Chip Creation [1] - Deputy General Manager Li Zuqing of Guangli Technology plans to reduce no more than 701,600 shares [1] Other Notable Events - Yuan Zhishuang of Dingxin Communications is under investigation by the Securities Regulatory Commission for suspected short-term trading of company shares [1] - Shimao Energy has terminated its plans for a change in control [1]

Group 1 - The core point of the article is that Opcon Vision has reported a total of 64,207 shareholders as of January 9, 2026 [2]

Group 1 - The core point of the article is that Opcon Vision has reported an expected total number of shareholders to reach 61,940 by December 31, 2025 [2]

Core Viewpoint - The company Ophthalmic Vision Technology Co., Ltd. (欧普康视) has shown a mixed financial performance with slight revenue growth but a significant decline in net profit, indicating potential challenges ahead in maintaining profitability while managing investor sentiment and market position [2][3]. Financing and Trading Activity - On January 6, the stock price of Ophthalmic Vision increased by 1.69%, with a trading volume of 463 million yuan. The financing buy-in amount for the day was 51.27 million yuan, while the financing repayment was 46.70 million yuan, resulting in a net financing buy of 457.09 thousand yuan. The total financing and securities balance reached 613 million yuan [1]. - The current financing balance of 609 million yuan accounts for 4.20% of the circulating market value, which is above the 60th percentile level over the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 900 shares were repaid, and 195,900 shares were sold short, amounting to 3.18 million yuan at the closing price. The remaining short selling volume was 269,000 shares, with a balance of 4.36 million yuan, also above the 50th percentile level over the past year [1]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 1.433 billion yuan, reflecting a year-on-year growth of 0.13%. However, the net profit attributable to shareholders decreased by 15.41% to 442 million yuan [2]. - Since its A-share listing, the company has distributed a total of 949 million yuan in dividends, with 576 million yuan distributed over the past three years [3]. Shareholder Structure - As of December 19, the number of shareholders for Ophthalmic Vision was 61,900, a slight decrease of 0.02% from the previous period. The average circulating shares per person increased by 0.02% to 10,797 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs, such as Huabao Zhongzheng Medical ETF and E Fund Growth ETF, while a new shareholder, Penghua Medical Technology Stock A, entered the top ten with 3.90 million shares [3].